Catherine Moukheibir - 06 Apr 2022 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Issuer symbol
MLTX
Transactions as of
06 Apr 2022
Net transactions value
$0
Form type
4
Filing time
05 May 2022, 17:47:33 UTC
Previous filing
15 Apr 2022
Next filing
03 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Award $0 +45,000 $0.000000 45,000 06 Apr 2022 Class A ordinary shares, par value $0.0001 per share 45,000 $12.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Moukheibir was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer.